Holen Sie sich die Stockscreener-App
135.38
1.52%
-2.09
Handel nachbörslich:
136.27
0.89
+0.66%
Schlusskurs vom Vortag:
$137.47
Offen:
$139.29
24-Stunden-Volumen:
459.86K
Relative Volume:
0.96
Marktkapitalisierung:
$3.91B
Einnahmen:
$267.23M
Nettoeinkommen (Verlust:
$-83.50M
KGV:
-43.53
EPS:
-3.11
Netto-Cashflow:
$-59.99M
1W Leistung:
+2.33%
1M Leistung:
-15.82%
6M Leistung:
+47.34%
1J Leistung:
+40.19%
1-Tages-Spanne:
$134.81
$140.83
1-Wochen-Bereich:
$124.26
$140.83
52-Wochen-Spanne:
$55.17
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Firmenname
Genedx Holdings Corp
Sektor
Branche
Telefon
888-729-1206
Adresse
333 LUDLOW STREET, STAMFORD
Vergleichen Sie WGS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
135.38 | 3.97B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-05-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-10 | Eingeleitet | Craig Hallum | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
Alle ansehen
Genedx Holdings Corp Aktie (WGS) Neueste Nachrichten
Why GeneDx Holdings Corp. stock could rally in 2025Swing Trade & Smart Money Movement Tracker - ulpravda.ru
Why GeneDx Holdings Corp. Equity Warrant stock is rated strong buyJuly 2025 Review & Stepwise Trade Signal Guides - ulpravda.ru
How GeneDx Holdings Corp. stock trades during market volatilityMarket Activity Summary & Reliable Price Breakout Signals - ulpravda.ru
Is GeneDx Holdings Corp. Equity Warrant stock positioned for digital transformation2025 Trading Volume Trends & Advanced Swing Trade Entry Plans - ulpravda.ru
GeneDx partners with Komodo Health to create comprehensive rare disease dataset - Investing.com Canada
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset - Business Wire
How GeneDx Holdings Corp. stock reacts to job market dataDividend Yield Trends & Free Unlock Rapid Growth Potential - ulpravda.ru
GeneDx Announces GenomeDx Prenatal, Expanding Genomic Diagnosis into Prenatal Care - MarketScreener
GeneDx to launch whole genome sequencing test for fetal anomalies By Investing.com - Investing.com Canada
New prenatal genome test offers faster answers after troubling ultrasounds - Stock Titan
A Look At GeneDx Holdings (WGS) Valuation After New CMO Appointment And Record Rare Disease Genomics Year - Yahoo Finance
GeneDx appoints Dr. Linda Genen as CMO - MSN
GeneDx Holdings Corp.Class A Common Stock (NQ: WGS - FinancialContent
GeneDx appoints Linda Genen as chief medical officer By Investing.com - Investing.com Australia
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care (2026-01-06) - Seeking Alpha
Should GeneDx’s GUARDIAN Newborn Genomics Accolade Reshape the Investment Narrative for WGS Investors? - simplywall.st
Genomic newborn screening may find serious diseases traditional tests miss - Stock Titan
(WGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Earnings Call Transcript - MSN
What Do Analysts Think About GeneDx Holdings Corp. (WGS)? - Insider Monkey
Simplify Asset Management Inc. Sells 41,071 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference - MarketScreener
Ajooni Biotech Limited Uptrend in Early Stages Indicators Say YesVolatility Index Analysis & You’ve Never Seen Stock Picks Like These - earlytimes.in
GeneDx Holdings Corp. $WGS Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Assenagon Asset Management S.A. Has $1.52 Million Stock Position in GeneDx Holdings Corp. $WGS - MarketBeat
Behavioral Patterns of WGS and Institutional Flows - Stock Traders Daily
What analysts say about GeneDx Holdings Corp Equity Warrant stockReal Estate Investment Trusts & Rapid Portfolio Appreciation - earlytimes.in
WGS FinancialsIncome Statement - Quiver Quantitative
GeneDx Holdings (WGS) Sees Analyst Rating Update: Price Target R - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) Stock - MarketBeat
Aug EndMonth: Is GeneDx Holdings Corp. Equity Warrant stock positioned well for digital economy2025 Price Action Summary & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Is JAMA’s GUARDIAN Nod Quietly Reframing GeneDx (WGS) as a Core Newborn Genomics Platform? - simplywall.st
Is GeneDx Holdings Corp. Equity Warrant stock a safe buy before earnings2025 Winners & Losers & Low Drawdown Investment Strategies - Улправда
Investment Report: How GeneDx Holdings Corp. Equity Warrant stock reacts to job market data2025 Top Gainers & Weekly High Conviction Trade Ideas - Улправда
GeneDx (WGS) Valuation Check as JAMA Highlights GUARDIAN Newborn Genomic Screening Study - simplywall.st
How GeneDx Holdings Corp. Equity Warrant stock reacts to job market data2025 Year in Review & Real-Time Buy Signal Notifications - Улправда
How sustainable is GeneDx Holdings Corp. stock dividend payoutJuly 2025 Earnings & Low Drawdown Trading Techniques - Улправда
Can GeneDx Holdings Corp. stock beat market expectations this quarter2025 Top Decliners & Low Risk Entry Point Guides - Улправда
Risk Report: Is GeneDx Holdings Corp. Equity Warrant stock attractive for income investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
Why analysts upgrade GeneDx Holdings Corp. stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - Улправда
Is GeneDx Holdings Corp. Equity Warrant stock positioned well for digital economyJuly 2025 Setups & Growth Oriented Trade Recommendations - Улправда
GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 10,857 Shares - MarketBeat
Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells 3,855 Shares of Stock - MarketBeat
GeneDx Holdings Corp. Executives Sell Shares for Tax Obligations - TradingView — Track All Markets
CFO Feeley Acquires 3,342 Of GeneDx Holdings Corp [WGS] - TradingView — Track All Markets
GeneDx Holdings Corp. (WGS) CFO reports RSU vesting and sell-to-cover trades - Stock Titan
GeneDx (WGS) CEO discloses RSU vesting, tax-related stock sales - Stock Titan
Can GeneDx Holdings Corp. Equity Warrant stock surprise with earnings upsideJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - Улправда
GeneDx (WGS) Stock Slides on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
GeneDx (NASDAQ:WGS) Stock Price Down 6.4%What's Next? - MarketBeat
WGS: Wells Fargo Raises Price Target to $155, Maintains Equal-We - GuruFocus
Finanzdaten der Genedx Holdings Corp-Aktie (WGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genedx Holdings Corp-Aktie (WGS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 16 '25 |
Sale |
143.87 |
3,855 |
554,616 |
8,731 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 16 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
25,094 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 16 '25 |
Sale |
143.89 |
10,857 |
1,562,185 |
14,237 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 09 '25 |
Option Exercise |
0.00 |
2,462 |
0 |
6,655 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 09 '25 |
Sale |
159.28 |
1,266 |
201,648 |
5,389 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 09 '25 |
Option Exercise |
0.00 |
6,547 |
0 |
9,983 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 09 '25 |
Sale |
159.28 |
3,639 |
579,620 |
6,344 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 01 '25 |
Option Exercise |
0.00 |
717 |
0 |
4,570 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 01 '25 |
Sale |
162.54 |
377 |
61,276 |
4,193 |
| RUCH JOSHUA | Director |
Nov 24 '25 |
Sale |
160.37 |
38,000 |
6,093,967 |
11,941 |
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):